Marvin Fritzler

List of Publications by Year in Descending Order

333 papers	17,052 citations	60 h-index	120 g-index
350 ext. papers	19,967 ext. citations	5.8 avg, IF	6.56 L-index

#	Paper	IF	Citations
333	Antinuclear antibodies (ANA) as a criterion for classification and diagnosis of systemic autoimmune diseases.. *Journal of Translational Autoimmunity*, **2022**, 5, 100145	4.1	2
332	Anti-synthetase syndrome occurring after SARS-CoV-2 infection.. *Scandinavian Journal of Rheumatology*, **2022**, 1-3	1.9	0
331	COVID-19-associated Critical Illness Myopathy with Direct Viral Effects.. *Annals of Neurology*, **2022**,	9.4	3
330	The International Consensus on ANA Patterns (ICAP) in 2021-The 6th Workshop and Current Perspectives.. *journal of applied laboratory medicine, The*, **2022**, 7, 322-330	2	6
329	Antinuclear Antibody Testing: Gold Standard Revisited.. *journal of applied laboratory medicine, The*, **2022**, 7, 357-361	2	1
328	Gaps and Trends in Autoantibody Testing.. *journal of applied laboratory medicine, The*, **2022**, 7, 362-366	2	1
327	Myositis with prominent B-cell aggregates causing shrinking lung syndrome in systemic lupus erythematosus: a case report.. *BMC Rheumatology*, **2022**, 6, 11	2.9	0
326	The Role of Autoantibody Testing in Modern Personalized Medicine.. *Clinical Reviews in Allergy and Immunology*, **2022**, 1	12.3	0
325	Comment on: Concordance between myositis autoantibodies and anti-nuclear antibody patterns in a real-world, Australian cohort.. *Rheumatology*, **2022**,	3.9	1
324	Prevalence and titres of antinuclear antibodies in juvenile idiopathic arthritis: A systematic review and meta-analysis.. *Autoimmunity Reviews*, **2022**, 103086	13.6	2
323	N-Formyl Methionine Peptide-Mediated Neutrophil Activation in Systemic Sclerosis.. *Frontiers in Immunology*, **2021**, 12, 785275	8.4	1
322	Immune-mediated Necrotizing Myopathy following BNT162b2 Vaccination in a Patient with Antibodies against Receptor-binding Domain of SARS-CoV-2 and Signal Recognition Particle.. *Muscle and Nerve*, **2021**,	3.4	0
321	Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19. *Nature Medicine*, **2021**,	50.5	16
320	Response to: Correspondence on ‘Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients’ by Trahtemberg. *Annals of the Rheumatic Diseases*, **2021**,	2.4	
319	Antiphospholipid Antibody Profiles and Thrombotic Outcomes in the Starlet Cohort of Patients with Systemic Lupus Erythematosus. *Blood*, **2021**, 138, 2126-2126	2.2	
318	Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies.. *Autoimmunity Reviews*, **2021**, 21, 103012	13.6	10
317	How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative. *Immunologic Research*, **2021**, 69, 594-608	4.3	11

316	COVID-19-associated autoimmunity as a feature of acute respiratory failure. *Intensive Care Medicine* , **2021**, 47, 801-804	14.5	8
315	Evaluation of a novel particle-based multi-analyte technology for the detection of anti-fibrillarin antibodies. *Immunologic Research*, **2021**, 69, 239-248	4.3	1
314	Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients. *Annals of the Rheumatic Diseases*, **2021**, 80, 1236-1240	2.4	15
313	Circulating Calprotectin as a Biomarker of COVID-19 Severity. *Expert Review of Clinical Immunology*, **2021**, 17, 431-443	5.1	21
312	Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic. *BMC Pulmonary Medicine*, **2021**, 21, 173	3.5	12
311	Autoantibody Discovery, Assay Development and Adoption: Death Valley, the Sea of Survival and Beyond. *Frontiers in Immunology*, **2021**, 12, 679613	8.4	5
310	Autoantibody profiles delineate distinct subsets of scleromyositis. *Rheumatology*, **2021**,	3.9	2
309	Histopathological features of systemic sclerosis-associated myopathy: A scoping review. *Autoimmunity Reviews*, **2021**, 20, 102851	13.6	3
308	Anti-Th/To Antibodies: Association With Lung Disease and Potential Protection From Systemic Sclerosis-Related Cancer? Comment on the Article by Mecoli et al. *Arthritis and Rheumatology*, **2021** , 73, 545-546	9.5	1
307	Comment on: The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. *Rheumatology*, **2021**, 60, e35-e37	3.9	3
306	Checkpoint inhibitors: Interface of cancer and autoimmunity: Opportunity for second level precision medicine **2021**, 109-134		
305	Challenges and Advances in SLE Autoantibody Detection and Interpretation **2021**, 67-91		0
304	Myositis in systemic lupus erythematosus. *Lupus*, **2021**, 30, 615-619	2.6	4
303	Development of multi-omics approach in autoimmune diseases **2021**, 189-201		1
302	Trigeminal neuralgia in systemic sclerosis. *Seminars in Arthritis and Rheumatism*, **2021**, 51, 318-323	5.3	
301	The antinuclear antibody HEp-2 indirect immunofluorescence assay: a survey of laboratory performance, pattern recognition and interpretation. *Autoimmunity Highlights*, **2021**, 12, 4	3.7	3
300	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. *Annals of the Rheumatic Diseases*, **2021**,	2.4	10
299	Do anti-DFS70 antibodies temper disease activity and progression in SLE?. *Lupus*, **2021**, 30, 852-853	2.6	0

298	Autoantibodies and cancer among asbestos-exposed cohorts in Western Australia. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **2021**, 84, 475-483	3.2	1
297	Metrics and definitions used in the assessment of cognitive impairment in systemic lupus erythematosus: A systematic review. *Seminars in Arthritis and Rheumatism*, **2021**, 51, 819-830	5.3	1
296	Thousands of CpGs Show DNA Methylation Differences in ACPA-Positive Individuals. *Genes*, **2021**, 12,	4.2	1
295	Longitudinal relationships between cognitive domains and DEPRESSION and anxiety symptoms in systemic lupus erythematosus. *Seminars in Arthritis and Rheumatism*, **2021**, 51, 1186-1192	5.3	1
294	High intelligence may exacerbate paediatric inflammatory response to SARS-CoV-2 infection. *Medical Hypotheses*, **2021**, 155, 110677	3.8	
293	Precision medicine as an approach to autoimmune diseases **2021**, 39-63		1
292	Validation of the automated neuropsychological assessment metrics for assessing cognitive impairment in systemic lupus erythematosus.. *Lupus*, **2021**, 9612033211062530	2.6	1
291	SARS-CoV-2 seroprevalence, seroconversion and neutralizing antibodies in a systemic lupus erythematosus cohort and comparison to controls. *Lupus*, **2021**, 9612033211063793	2.6	1
290	Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets. *Autoimmunity Reviews*, **2020**, 19, 102583	13.6	13
289	Precision health: A pragmatic approach to understanding and addressing key factors in autoimmune diseases. *Autoimmunity Reviews*, **2020**, 19, 102508	13.6	15
288	Investigating associations between anti-nuclear antibody positivity and combined long-term exposures to NO, O, and PM using a Bayesian kernel machine regression approach. *Environment International*, **2020**, 136, 105472	12.9	12
287	Reply. *Arthritis Care and Research*, **2020**, 72, 734-735	4.7	
286	Assessment of antinuclear antibodies by indirect immunofluorescence assay: report from a survey by the American Association of Medical Laboratory Immunologists. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, 1489-1497	5.9	7
285	Establishment of international autoantibody reference standards for the detection of autoantibodies directed against PML bodies, GW bodies, and NuMA protein. *Clinical Chemistry and Laboratory Medicine*, **2020**, 59, 197-207	5.9	2
284	A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus. *Autoimmunity Reviews*, **2020**, 19, 102463	13.6	31
283	Autoantibody Assays: Performance, Interpretation, and Standardization **2020**, 1369-1389		
282	Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. *Arthritis Research and Therapy*, **2020**, 22, 5	5.7	29
281	2020 international consensus on ANCA testing beyond systemic vasculitis. *Autoimmunity Reviews*, **2020**, 19, 102618	13.6	36

280	Long-term exposure to a mixture of industrial SO, NO, and PM and anti-citrullinated protein antibody positivity. *Environmental Health*, **2020**, 19, 86	6	8
279	Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies. *RMD Open*, **2020**, 6,	5.9	9
278	Antinuclear antibodies by indirect immunofluorescence and solid phase assays. *Annals of the Rheumatic Diseases*, **2020**, 79, e65	2.4	14
277	Validity Evidence for the Use of Automated Neuropsychologic Assessment Metrics As a Screening Tool for Cognitive Impairment in Systemic Lupus Erythematosus. *Arthritis Care and Research*, **2020**, 72, 1809-1819	4.7	9
276	Professional Insights from a Pioneer in Autoimmune Disease Testing: The Future of Antinuclear/Anticellular Antibody Testing. *journal of applied laboratory medicine, The*, **2019**, 4, 287-289	2	2
275	Harmonization of clinical interpretation of antinuclear antibody test results by solid phase assay and by indirect immunofluorescence through likelihood ratios. *Autoimmunity Reviews*, **2019**, 18, 102386	13.6	20
274	Autoantibody status is not associated with change in lung function or survival in patients with idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2019**, 153, 85-90	4.6	3
273	Autoantibodies to a novel Rpp38 (Th/To) derived B-cell epitope are specific for systemic sclerosis and associate with a distinct clinical phenotype. *Rheumatology*, **2019**, 58, 1784-1793	3.9	2
272	Scurfy Mice Develop Features of Connective Tissue Disease Overlap Syndrome and Mixed Connective Tissue Disease in the Absence of Regulatory T Cells. *Frontiers in Immunology*, **2019**, 10, 881	8.4	4
271	Challenges and Advances in SLE Autoantibody Detection and Interpretation. *Current Treatment Options in Rheumatology*, **2019**, 5, 147-167	1.3	6
270	Establishment of an international autoantibody reference standard for human anti-DFS70 antibodies: proof-of-concept study for a novel Megapool strategy by pooling individual specific sera. *Clinical Chemistry and Laboratory Medicine*, **2019**, 57, 1754-1763	5.9	10
269	The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center Study. *Frontiers in Immunology*, **2019**, 10, 662	8.4	11
268	Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis. *Frontiers in Immunology*, **2019**, 10, 745	8.4	17
267	Implications for redefining the dense fine speckled and related indirect immunofluorescence patterns. *Expert Review of Clinical Immunology*, **2019**, 15, 447-448	5.1	5
266	Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. *Annals of the Rheumatic Diseases*, **2019**, 78, 879-889	2.4	128
265	Autoantibodies to Mi-2 alpha and Mi-2 beta in patients with idiopathic inflammatory myopathy. *Rheumatology*, **2019**, 58, 1655-1661	3.9	12
264	A case of aggressive atypical anti-GBM disease complicated by CMV pneumonitis. *BMC Nephrology*, **2019**, 20, 29	2.7	4
263	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. *Arthritis Care and Research*, **2019**, 71, 893-902	4.7	46

262	KSHV RNA-binding protein ORF57 inhibits P-body formation to promote viral multiplication by interaction with Ago2 and GW182. *Nucleic Acids Research*, **2019**, 47, 9368-9385	20.1	13
261	Autoantibodies in SLE: prediction and the value matrix. *Lupus*, **2019**, 28, 1285-1293	2.6	18
260	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Annals of the Rheumatic Diseases*, **2019**, 78, 1151-1159	2.4	344
259	Rheumatoid arthritis-relevant DNA methylation changes identified in ACPA-positive asymptomatic individuals using methylome capture sequencing. *Clinical Epigenetics*, **2019**, 11, 110	7.7	11
258	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. *Arthritis and Rheumatology*, **2019**, 71, 1400-1412	9.5	488
257	A Monoclonal Antibody to M-Phase Phosphoprotein 1/Kinesin-Like Protein KIF20B. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy*, **2019**, 38, 162-170	1.9	1
256	Autoantibodies to mRNA processing pathways (glycine and tryptophan-rich bodies antibodies): prevalence and clinical utility in a South Australian cohort. *Pathology*, **2019**, 51, 723-726	1.6	
255	Expression of a constitutively active human mutant in hematopoietic cells produces an -dependent vasculopathy in mice. *Life Science Alliance*, **2019**, 2,	5.8	10
254	Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness. *Expert Review of Clinical Immunology*, **2019**, 15, 241-250	5.1	35
253	Detection of myositis-specific antibodies: additional notes. *Annals of the Rheumatic Diseases*, **2019**, 78, e45	2.4	21
252	Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?. *Annals of the Rheumatic Diseases*, **2019**, 78, e46	2.4	28
251	Reference standards for the detection of anti-mitochondrial and anti-rods/rings autoantibodies. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, 1789-1798	5.9	13
250	Diagnostic Utility of Anticarbamylated Protein Antibodies as Measured Using Carbamylated Fetal Calf Serum. *Journal of Rheumatology*, **2018**, 45, 438-439	4.1	3
249	The Antinuclear Antibody Test in the Diagnosis of Antisynthetase Syndrome and Other Autoimmune Myopathies. *Journal of Rheumatology*, **2018**, 45, 444-445	4.1	11
248	International Consensus on Antinuclear Antibody Patterns: defining negative results and reporting unidentified patterns. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, 1799-1802	5.9	18
247	Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype. *Autoimmunity Reviews*, **2018**, 17, 267-275	13.6	15
246	Solid phase assays versus automated indirect immunofluorescence for detection of antinuclear antibodies. *Autoimmunity Reviews*, **2018**, 17, 533-540	13.6	40
245	Autoantibodies to the survival of motor neuron complex in a patient with necrotizing autoimmune myopathy. *Rheumatology*, **2018**, 57, 199-200	3.9	6

244	Describing and expanding the clinical phenotype of anti-MDA5-associated rapidly progressive interstitial lung disease: case series of nine Canadian patients and literature review. *Scandinavian Journal of Rheumatology*, **2018**, 47, 210-224	1.9	20
243	Redefining systemic lupus erythematosus - SMAARTT proteomics. *Nature Reviews Rheumatology*, **2018**, 14, 451-452	8.1	14
242	Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS). *PLoS ONE*, **2018**, 13, e0193960	3.7	11
241	The Utilization of Autoantibodies in Approaches to Precision Health. *Frontiers in Immunology*, **2018**, 9, 2682	8.4	21
240	Analysis of autoantibody profiles in two asbestiform fiber exposure cohorts. *Journal of Toxicology and Environmental Health - Part A: Current Issues*, **2018**, 81, 1015-1027	3.2	5
239	The clinical utility of anti-double-stranded DNA antibodies and the challenges of their determination. *Journal of Immunological Methods*, **2018**, 459, 11-19	2.5	40
238	International consensus on antinuclear antibody patterns: definition of the AC-29 pattern associated with antibodies to DNA topoisomerase I. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, 1783-1788	5.9	32
237	The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. *Lupus*, **2017**, 26, 1051-1059	2.6	37
236	Antifibrillarin Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis. *Journal of Rheumatology*, **2017**, 44, 799-805	4.1	14
235	Commentary on the recent international multicentre study (EUVAS) on antineutrophil cytoplasmic antibodies. *Annals of the Rheumatic Diseases*, **2017**, 76, e38	2.4	2
234	Emerging technologies in autoantibody testing for rheumatic diseases. *Arthritis Research and Therapy*, **2017**, 19, 172	5.7	32
233	Prevalence of Systemic Sclerosis in Primary Biliary Cholangitis Using the New ACR/EULAR Classification Criteria. *Journal of Rheumatology*, **2017**, 44, 33-39	4.1	18
232	Dr Eng M. Tan: a tribute to an enduring legacy in autoimmunity. *Lupus*, **2017**, 26, 208-217	2.6	
231	Relationship between calcium channel blockers and skin fibrosis in patients with systemic sclerosis. *Clinical and Experimental Rheumatology*, **2017**, 35 Suppl 106, 56-60	2.2	2
230	The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. *Clinical and Experimental Medicine*, **2016**, 16, 273-93	4.9	50
229	Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. *Medicine (United States)*, **2016**, 95, e4713	1.8	36
228	Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care. *Lupus*, **2016**, 25, 838-49	2.6	29
227	Clinical and serological associations of autoantibodies to the Ku70/Ku80 heterodimer determined by a novel chemiluminescent immunoassay. *Lupus*, **2016**, 25, 889-96	2.6	7

226	Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. *Lupus*, **2016**, 25, 797-804	2.6	62
225	Development and multi-center evaluation of a novel immunoadsorption method for anti-DFS70 antibodies. *Lupus*, **2016**, 25, 897-904	2.6	15
224	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. *Arthritis Research and Therapy*, **2016**, 18, 20	5.7	13
223	Autoantibodies directed to centromere protein F in a patient with BRCA1 gene mutation. *BMC Research Notes*, **2016**, 9, 84	2.3	
222	Improving Appropriate Access to Care With Central Referral and Triage in Rheumatology. *Arthritis Care and Research*, **2016**, 68, 1547-53	4.7	23
221	Detection of autoantibodies using chemiluminescence technologies. *Immunopharmacology and Immunotoxicology*, **2016**, 38, 14-20	3.2	27
220	Choosing wisely: Review and commentary on anti-nuclear antibody (ANA) testing. *Autoimmunity Reviews*, **2016**, 15, 272-80	13.6	51
219	International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. *Autoimmunity Highlights*, **2016**, 7, 1	3.7	86
218	Towards a better understanding of the clinical association of anti-DFS70 autoantibodies. *Autoimmunity Reviews*, **2016**, 15, 198-201	13.6	40
217	Anti-HMGCR antibodies in systemic sclerosis. *Medicine (United States)*, **2016**, 95, e5280	1.8	4
216	Subsets in systemic sclerosis: one size does not fit all. *Journal of Scleroderma and Related Disorders*, **2016**, 1, 298-306	2.3	7
215	Anti-early endosome antigen 1 autoantibodies were detected in a pemphigus-like patient but not in the majority of pemphigus diseases. *Experimental Dermatology*, **2016**, 25, 368-74	4	
214	Progress in understanding the diagnostic and pathogenic role of autoantibodies associated with systemic sclerosis. *Current Opinion in Rheumatology*, **2016**, 28, 586-94	5.3	25
213	Recognition of the dense fine speckled (DFS) pattern remains challenging: results from an international internet-based survey. *Autoimmunity Highlights*, **2016**, 7, 8	3.7	39
212	Calcinosis is associated with digital ischaemia in systemic sclerosis-a longitudinal study. *Rheumatology*, **2016**, 55, 2148-2155	3.9	39
211	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. *Autoimmunity Reviews*, **2016**, 15, 983-93	13.6	76
210	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. *Lancet Respiratory Medicine,the*, **2016**, 4, 708-719	35.1	487
209	Autoantibodies in systemic sclerosis: unanswered questions. *Frontiers in Immunology*, **2015**, 6, 167	8.4	61

208	Antinuclear antibody-negative systemic sclerosis. *Seminars in Arthritis and Rheumatism*, **2015**, 44, 680-6	5.3	43
207	Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. *Seminars in Arthritis and Rheumatism*, **2015**, 45, 184-9	5.3	18
206	Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls. *Journal of Rheumatology* , **2015**, 42, 2419-26	4.1	28
205	Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. *Autoimmunity*, **2015**, 48, 542-51	3	18
204	2013 American College of Rheumatology/European League against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research Group. *Arthritis Care and Research*, **2015**, 67, 582-7	4.7	51
203	Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015. *Frontiers in Immunology*, **2015**, 6, 412	8.4	193
202	Evidence for Epigenetic Regulation of Gene Expression and Function in Chronic Experimental Diabetic Neuropathy. *Journal of Neuropathology and Experimental Neurology*, **2015**, 74, 804-17	3.1	45
201	Clinical and serological analysis of patients with positive anticyclic citrullinated Peptide antibodies referred through a Rheumatology Central Triage System. *Journal of Rheumatology*, **2015**, 42, 771-7	4.1	3
200	Autoantibodies to the mitochondrial RNA processing (MRP) complex also known as Th/To autoantigen. *Autoimmunity Reviews*, **2015**, 14, 254-7	13.6	22
199	Autoantibodies 2015: From diagnostic biomarkers toward prediction, prognosis and prevention. *Autoimmunity Reviews*, **2015**, 14, 555-63	13.6	59
198	Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. *Clinical and Experimental Rheumatology*, **2015**, 33, S131-5	2.2	22
197	Autoantibody Assays **2014**, 1161-1175		
196	Development and validation of a lateral flow assay (LFA) for the determination of IgG-antibodies to Pr3 (cANCA) and MPO (pANCA). *Journal of Immunological Methods*, **2014**, 403, 1-6	2.5	10
195	Diagnostic criteria of systemic sclerosis. *Journal of Autoimmunity*, **2014**, 48-49, 38-41	15.5	31
194	Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. *Autoimmunity Reviews*, **2014**, 13, 367-71	13.6	183
193	Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects. *Journal of Rheumatology*, **2014**, 41, 2179-85	4.1	40
192	International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. *Annals of the Rheumatic Diseases*, **2014**, 73, 17-23	2.4	360
191	Phospholipid-binding proteins differ in their capacity to induce autoantibodies and murine systemic lupus erythematosus. *Lupus*, **2014**, 23, 752-68	2.6	9

190	Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?. *Nature Reviews Rheumatology*, **2014**, 10, 682-90	8.1	14
189	Autoantibodies to the Rpp25 component of the Th/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests. *Journal of Rheumatology*, **2014**, 41, 1334-43	4.1	16
188	Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. *Arthritis and Rheumatology*, **2014**, 66, 1608-15	9.5	71
187	PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC). *PLoS ONE*, **2014**, 9, e112877	3.7	43
186	Systemic sclerosis immunoglobulin induces growth and a pro-fibrotic state in vascular smooth muscle cells through the epidermal growth factor receptor. *PLoS ONE*, **2014**, 9, e100035	3.7	11
185	Golgi Complex and Endosome Antibodies **2014**, 265-273		
184	Autoantibodies to GW/P Bodies and Components of the MicroRNA Pathway **2014**, 257-263		1
183	The spectrum of anti-chromatin/nucleosome autoantibodies: independent and interdependent biomarkers of disease. *Journal of Immunology Research*, **2014**, 2014, 368274	4.5	25
182	Absence of an association between anti-Ro antibodies and prolonged QTc interval in systemic sclerosis: a multicenter study of 689 patients. *Seminars in Arthritis and Rheumatism*, **2014**, 44, 338-44	5.3	22
181	Ultrastructural characterization of primary cilia in pathologically characterized human glioblastoma multiforme (GBM) tumors. *BMC Clinical Pathology*, **2014**, 14, 40	3	30
180	An autoimmune myositis-overlap syndrome associated with autoantibodies to nuclear pore complexes: description and long-term follow-up of the anti-Nup syndrome. *Medicine (United States)*, **2014**, 93, 383-394	1.8	8
179	Mammalian microtubule P-body dynamics are mediated by nesprin-1. *Journal of Cell Biology*, **2014**, 205, 457-75	7.3	22
178	Antinucleolar Antibodies as Diagnostic Markers in Systemic Autoimmune Diseases **2014**, 145-150		
177	Antiphospholipase A□receptor autoantibodies: a comparison of three different immunoassays for the diagnosis of idiopathic membranous nephropathy. *Journal of Immunology Research*, **2014**, 2014, 143274	4.5	46
176	Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. *Journal of Immunology Research*, **2014**, 2014, 315179	4.5	114
175	Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies. *PLoS ONE*, **2014**, 9, e93812	3.7	50
174	Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay. *Arthritis Research and Therapy*, **2013**, 15, R50	5.7	17
173	Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection. *BMC Gastroenterology*, **2013**, 13, 50	3	23

172	Reflections on ten years of history of, and future prospects for, GW182 and GW/P body research. *Advances in Experimental Medicine and Biology*, **2013**, 768, 261-70	3.6	3
171	The discovery of GW bodies. *Advances in Experimental Medicine and Biology*, **2013**, 768, 5-21	3.6	7
170	Autoantibodies in systemic sclerosis. *Autoimmunity Reviews*, **2013**, 12, 340-54	13.6	151
169	Relationship of other cytoplasmic ribonucleoprotein bodies (cRNPB) to GW/P bodies. *Advances in Experimental Medicine and Biology*, **2013**, 768, 213-42	3.6	18
168	An SNP in the trinucleotide repeat region of the TNRC6A gene maps to a major TNGW1 autoepitope in patients with autoantibodies to GW182. *Advances in Experimental Medicine and Biology*, **2013**, 768, 243-59	3.6	1
167	Reflections on Lupus 2013: butterflies, wolves and prophecies. *Lupus*, **2013**, 22, 1092-101	2.6	1
166	Clinical phenotypes of patients with anti-DFS70/LEDGF antibodies in a routine ANA referral cohort. *Clinical and Developmental Immunology*, **2013**, 2013, 703759		51
165	Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. *Autoimmunity Reviews*, **2012**, 11, 642-5	13.6	74
164	Prevalence of systemic lupus erythematosus and systemic sclerosis in the First Nations population of Alberta, Canada. *Arthritis Care and Research*, **2012**, 64, 138-43	4.7	48
163	Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent. *Autoimmunity Highlights*, **2012**, 3, 51-8	3.7	28
162	The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA). *Autoimmunity Reviews*, **2012**, 11, 771-5	13.6	41
161	Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. *Arthritis Research and Therapy*, **2012**, 14, R50	5.7	80
160	Chronic smoke exposure induces rheumatoid factor and anti-heat shock protein 70 autoantibodies in susceptible mice and humans with lung disease. *European Journal of Immunology*, **2012**, 42, 1051-61	6.1	28
159	Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope. *Rheumatology International*, **2012**, 32, 691-8	3.6	13
158	Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. *Journal of Rheumatology*, **2012**, 39, 787-94	4.1	34
157	The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. *Clinical and Developmental Immunology*, **2012**, 2012, 494356		68
156	Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. *Journal of Rheumatology*, **2012**, 39, 2104-10	4.1	99
155	Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA. *Clinica Chimica Acta*, **2011**, 412, 1937-43	6.2	30

154	Antihistone and Antispliceosomal Antibodies **2011**, 275-292		2
153	Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis. *Clinical and Experimental Immunology*, **2011**, 163, 147-56	6.2	37
152	Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. *Autoimmunity Reviews*, **2011**, 10, 194-200	13.6	58
151	Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis. *Journal of Rheumatology*, **2011**, 38, 1622-30	4.1	31
150	Repression of GW/P body components and the RNAi microprocessor impacts primary ciliogenesis in human astrocytes. *BMC Cell Biology*, **2011**, 12, 37		13
149	Epitope specificity and significance in systemic autoimmune diseases. *Annals of the New York Academy of Sciences*, **2010**, 1183, 267-87	6.5	88
148	The microRNA and messengerRNA profile of the RNA-induced silencing complex in human primary astrocyte and astrocytoma cells. *PLoS ONE*, **2010**, 5, e13445	3.7	25
147	Cytoplasmic ribonucleoprotein (RNP) bodies and their relationship to GW/P bodies. *International Journal of Biochemistry and Cell Biology*, **2010**, 42, 828-43	5.6	67
146	Clinical and serological evaluation of a novel CENP-A peptide based ELISA. *Arthritis Research and Therapy*, **2010**, 12, R99	5.7	19
145	Novel diagnostic and clinical aspects of anti-PCNA antibodies detected by novel detection methods. *Lupus*, **2010**, 19, 1527-33	2.6	22
144	Systemic sclerosis: establishing diagnostic criteria. *Medicine (United States)*, **2010**, 89, 159-165	1.8	36
143	Comparison between multiplex assays for autoantibody detection in systemic lupus erythematosus. *Journal of Immunological Methods*, **2010**, 358, 75-80	2.5	63
142	Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality?. *Autoimmunity Reviews*, **2010**, 9, 756-60	13.6	40
141	Autoantibodies in pediatric systemic lupus erythematosus: ethnic grouping, cluster analysis, and clinical correlations. *Journal of Rheumatology*, **2009**, 36, 416-21	4.1	52
140	Microbead-based technologies in diagnostic autoantibody detection. *Expert Opinion on Medical Diagnostics*, **2009**, 3, 81-9		20
139	The C-terminal half of human Ago2 binds to multiple GW-rich regions of GW182 and requires GW182 to mediate silencing. *Rna*, **2009**, 15, 804-13	5.8	101
138	Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. *Journal of Rheumatology*, **2009**, 36, 2250-6	4.1	81
137	Primary ciliogenesis defects are associated with human astrocytoma/glioblastoma cells. *BMC Cancer*, **2009**, 9, 448	4.8	78

136	PM1-Alpha ELISA: the assay of choice for the detection of anti-PM/Scl autoantibodies?. *Autoimmunity Reviews*, **2009**, 8, 373-8	13.6	20
135	Optimization of immunoprecipitation-western blot analysis in detecting GW182-associated components of GW/P bodies. *Nature Protocols*, **2009**, 4, 674-85	18.8	22
134	The changing landscape of the clinical value of the PM/Scl autoantibody system. *Arthritis Research and Therapy*, **2009**, 11, 106	5.7	15
133	GW bodies: cytoplasmic compartments in normal human skin. *Journal of Investigative Dermatology*, **2008**, 128, 2909-12	4.3	1
132	Challenges to the use of autoantibodies as predictors of disease onset, diagnosis and outcomes. *Autoimmunity Reviews*, **2008**, 7, 616-20	13.6	53
131	Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. *Arthritis Research and Therapy*, **2008**, 10, R131	5.7	65
130	Identification of GW182 and its novel isoform TNGW1 as translational repressors in Ago2-mediated silencing. *Journal of Cell Science*, **2008**, 121, 4134-44	5.3	55
129	A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. *Clinical Rheumatology*, **2008**, 27, 77-83	3.9	71
128	Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. *Arthritis and Rheumatism*, **2008**, 58, 3902-12		375
127	Association of autoantibodies with Ku and DNA repair proteins in connective tissue diseases. *Rheumatology*, **2008**, 47, 165-71	3.9	31
126	Systemic Sclerosis **2008**, 31-36		
125	Type I IFN-mediated Inhibition of Inflammatory Th cell Responses by a Subset of SLE Patient Sera. *FASEB Journal*, **2008**, 22, 669.16	0.9	
124	The role of GW/P-bodies in RNA processing and silencing. *Journal of Cell Science*, **2007**, 120, 1317-23	5.3	107
123	Markers of mRNA stabilization and degradation, and RNAi within astrocytoma GW bodies. *Journal of Neuroscience Research*, **2007**, 85, 3619-31	4.4	31
122	AutoAbSC.Org -- Autoantibody Standardization Committee in 2006. *Autoimmunity Reviews*, **2007**, 6, 577-80	3.6	49
121	A clinical approach to autoantibody testing in systemic autoimmune rheumatic disorders. *Autoimmunity Reviews*, **2007**, 7, 77-84	13.6	55
120	Clinical and serological features of patients with autoantibodies to GW/P bodies. *Clinical Immunology*, **2007**, 125, 247-56	9	84
119	Diverse humoral autoimmunity to the ribosomal P proteins in systemic lupus erythematosus and hepatitis C virus infection. *Journal of Molecular Medicine*, **2007**, 85, 953-9	5.5	9

118	A case of limited cutaneous systemic sclerosis developing anti-mitochondria antibody positive primary biliary cirrhosis after acute myocardial infarction. *Clinical Rheumatology*, **2007**, 26, 1571-4	3.9	5
117	The development of systemic sclerosis classification criteria. *Clinical Rheumatology*, **2007**, 26, 1401-9	3.9	45
116	Synthetic peptides: the future of patient management in systemic rheumatic diseases?. *Current Medicinal Chemistry*, **2007**, 14, 2831-8	4.3	26
115	Anti-dsDNA antibody testing in the clinic: Farr or ELISA?. *Nature Clinical Practice Rheumatology*, **2007**, 3, 72-3		22
114	Small interfering RNA-mediated silencing induces target-dependent assembly of GW/P bodies. *Molecular Biology of the Cell*, **2007**, 18, 3375-87	3.5	42
113	Challenges and Controversies in Autoantibodies Associated with Systemic Rheumatic Diseases. *Current Rheumatology Reviews*, **2007**, 3, 67-78	1.6	12
112	GW BODIES, P BODIES AND COMPONENTS OF THE miRNA PATHWAY **2007**, 257-262		
111	GOLGI COMPLEX AND ENDOSOME ANTIBODIES **2007**, 263-270		1
110	Update on autoantibodies in systemic sclerosis. *Current Opinion in Rheumatology*, **2007**, 19, 580-91	5.3	50
109	Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. *Arthritis Research and Therapy*, **2007**, 9, R78	5.7	138
108	Advances in understanding newer autoantibodies and their role as biomarkers in systemic lupus erythematosus. *Expert Opinion on Medical Diagnostics*, **2007**, 1, 393-408		3
107	Autoantibodies in lupus nephritis patients requiring renal transplantation. *Lupus*, **2007**, 16, 394-400	2.6	31
106	Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. *Journal of Rheumatology*, **2007**, 34, 1528-34	4.1	47
105	Analysis of human sera that are polyreactive in an addressable laser bead immunoassay. *Clinical Immunology*, **2006**, 120, 349-56	9	15
104	Detection of the argonaute protein Ago2 and microRNAs in the RNA induced silencing complex (RISC) using a monoclonal antibody. *Journal of Immunological Methods*, **2006**, 317, 38-44	2.5	66
103	GW bodies, microRNAs and the cell cycle. *Cell Cycle*, **2006**, 5, 242-5	4.7	41
102	The emergence of multiplexed technologies as diagnostic platforms in systemic autoimmune diseases. *Current Medicinal Chemistry*, **2006**, 13, 2503-12	4.3	47
101	International multicenter evaluation of autoantibodies to ribosomal P proteins. *Vaccine Journal*, **2006**, 13, 77-83		69

100	Advances and applications of multiplexed diagnostic technologies in autoimmune diseases. *Lupus*, **2006**, 15, 422-7	2.6	62
99	Autoimmune targeting of key components of RNA interference. *Arthritis Research and Therapy*, **2006**, 8, R87	5.7	86
98	Human autoantibodies against early endosome antigen-1 enhance excitatory synaptic transmission. *Neuroscience*, **2006**, 143, 953-64	3.9	15
97	Human autoantibodies to diacyl-phosphatidylethanolamine recognize a specific set of discrete cytoplasmic domains. *Clinical and Experimental Immunology*, **2006**, 143, 572-84	6.2	16
96	Anti-p97/VCP antibodies: an autoantibody marker for a subset of primary biliary cirrhosis patients with milder disease?. *Scandinavian Journal of Immunology*, **2006**, 63, 376-82	3.4	22
95	Formation of GW bodies is a consequence of microRNA genesis. *EMBO Reports*, **2006**, 7, 904-10	6.5	102
94	Autoantibody Assays, Testing, and Standardization **2006**, 1011-1022		6
93	Identification of GRASP-1 as a novel 97 kDa autoantigen localized to endosomes. *Clinical Immunology*, **2005**, 116, 108-17	9	10
92	Stress granules and processing bodies are dynamically linked sites of mRNP remodeling. *Journal of Cell Biology*, **2005**, 169, 871-84	7.3	1047
91	Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen. *Arthritis Research*, **2005**, 7, R704-13		40
90	Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies. *Arthritis Research*, **2005**, 7, R19-29		59
89	Major immunoreactive domains of human ribosomal P proteins lie N-terminal to a homologous C-22 sequence: application to a novel ELISA for systemic lupus erythematosus. *Clinical and Experimental Immunology*, **2005**, 141, 155-64	6.2	20
88	Disruption of GW bodies impairs mammalian RNA interference. *Nature Cell Biology*, **2005**, 7, 1267-74	23.4	368
87	Unique and shared features of Golgi complex autoantigens. *Autoimmunity Reviews*, **2005**, 4, 35-41	13.6	37
86	Improved serological differentiation between systemic lupus erythematosus and mixed connective tissue disease by use of an SmD3 peptide-based immunoassay. *Vaccine Journal*, **2005**, 12, 107-13		24
85	GW182 is critical for the stability of GW bodies expressed during the cell cycle and cell proliferation. *Journal of Cell Science*, **2004**, 117, 5567-78	5.3	164
84	The nuclear pore complex protein Tpr is a common autoantigen in sera that demonstrate nuclear envelope staining by indirect immunofluorescence. *Clinical and Experimental Immunology*, **2004**, 136, 379-87	6.2	29
83	Autoantibodies from primary biliary cirrhosis patients with anti-p95c antibodies bind to recombinant p97/VCP and inhibit in vitro nuclear envelope assembly. *Clinical and Experimental Immunology*, **2004**, 136, 568-73	6.2	26

82	Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. *Seminars in Arthritis and Rheumatism*, **2004**, 34, 501-37	5.3	446
81	Altered neurological function in mice immunized with early endosome antigen 1. *BMC Neuroscience* , **2004**, 5, 2	3.2	11
80	Autoantigens of the nuclear pore complex. *Journal of Molecular Medicine*, **2004**, 82, 423-33	5.5	30
79	Cutting edge diagnostics in rheumatology: the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology. *Arthritis and Rheumatism*, **2004**, 51, 291-8		64
78	Technical and clinical evaluation of anti-ribosomal P protein immunoassays. *Journal of Clinical Laboratory Analysis*, **2004**, 18, 215-23	3	31
77	Giantin is the major Golgi autoantigen in human anti-Golgi complex sera. *Arthritis Research*, **2004**, 6, R95-102		34
76	Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes, and GW bodies. *Clinical Immunology*, **2004**, 110, 30-44	9	68
75	Characterization of early endosome antigen 1 in neural tissues. *Biochemical and Biophysical Research Communications*, **2004**, 323, 1334-42	3.4	7
74	ANTIBODIES TO NONHISTONE ANTIGENS IN SYSTEMIC LUPUS ERYTHEMATOSUS **2004**, 349-376		
73	A proposal of criteria for the classification of systemic sclerosis. *Medical Science Monitor*, **2004**, 10, CR615-21	3.2	31
72	A panel of monoclonal antibodies to cytoplasmic GW bodies and the mRNA binding protein GW182. *Hybridoma*, **2003**, 22, 79-86		27
71	The GW182 protein colocalizes with mRNA degradation associated proteins hDcp1 and hLSm4 in cytoplasmic GW bodies. *Rna*, **2003**, 9, 1171-3	5.8	212
70	Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins. *Journal of Molecular Medicine*, **2003**, 81, 194-204	5.5	56
69	Clinical and serological associations of autoantibodies to GW bodies and a novel cytoplasmic autoantigen GW182. *Journal of Molecular Medicine*, **2003**, 81, 811-8	5.5	56
68	Spectrum of centrosome autoantibodies in childhood varicella and post-varicella acute cerebellar ataxia. *BMC Pediatrics*, **2003**, 3, 11	2.6	25
67	Identification of the B-cell epitopes of the early endosome antigen 1 (EEA1). *Clinical Immunology*, **2003**, 109, 154-64	9	25
66	The use and abuse of commercial kits used to detect autoantibodies. *Arthritis Research*, **2003**, 5, 192-201		52
65	Advances in understanding and use of autoantibodies as markers of diseases **2003**, 29-42		1

64	A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturersR laboratories. *Journal of Rheumatology*, **2003**, 30, 2374-81	4.1	43
63	Anti-mitochondrial autoantibodies. *Clinical and Applied Immunology Reviews*, **2002**, 3, 87-113		21
62	Specificity of autoantibodies to SS-A/Ro on a transfected and overexpressed human 60 kDa Ro autoantigen substrate. *Journal of Clinical Laboratory Analysis*, **2002**, 16, 103-8	3	27
61	The cytoplasmic linker protein CLIP-170 is a human autoantigen. *Clinical and Experimental Immunology*, **2002**, 127, 533-8	6.2	21
60	A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles. *Molecular Biology of the Cell*, **2002**, 13, 1338-51	3.5	296
59	A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content. *Journal of Rheumatology*, **2002**, 29, 68-74	4.1	41
58	Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. *Seminars in Arthritis and Rheumatism*, **2001**, 30, 332-46	5.3	184
57	Autoantibodies in childhood post-varicella acute cerebellar ataxia. *Canadian Journal of Neurological Sciences*, **2000**, 27, 316-20	1	33
56	Autoantibodies to early endosome antigen (EEA1) produce a staining pattern resembling cytoplasmic anti-neutrophil cytoplasmic antibodies (C-ANCA). *Clinical and Experimental Immunology*, **2000**, 122, 493-8	6.2	14
55	Human autoantibodies to a novel Golgi protein golgin-67: high similarity with golgin-95/gm 130 autoantigen. *Journal of Autoimmunity*, **2000**, 14, 179-87	15.5	31
54	Urinary mercury levels in patients with autoantibodies to U3-RNP (fibrillarin). *Journal of Rheumatology*, **2000**, 27, 405-10	4.1	26
53	Autoantibodies from patients with idiopathic ataxia bind to M-phase phosphoprotein-1 (MPP1). *Journal of Investigative Medicine*, **2000**, 48, 28-39	2.9	14
52	A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. *Arthritis and Rheumatism*, **1999**, 42, 455-64		143
51	Early endosome antigen. 1: An autoantigen associated with neurological diseases. *Journal of Investigative Medicine*, **1999**, 47, 311-8	2.9	28
50	Autoantibodies to components of the mitotic apparatus. *Molecular Biology Reports*, **1998**, 25, 143-55	2.8	16
49	Autoantibodies to a group of centrosomal proteins in human autoimmune sera reactive with the centrosome. *Arthritis and Rheumatism*, **1998**, 41, 551-8		77
48	Advances in autoantibodies in SLE. *Lupus*, **1998**, 7, 507-14	2.6	13
47	The frequency of phospholipid antibodies in an unselected stroke population. *Canadian Journal of Neurological Sciences*, **1998**, 25, 64-9	1	52

46	Golgins: coiled-coil-rich proteins associated with the Golgi Complex. *Electronic Journal of Biotechnology*, **1998**, 1, 45-54	3.1	16
45	Autoantibodies to a group of centrosomal proteins in human autoimmune sera reactive with the centrosome **1998**, 41, 551		3
44	The relationship of ASE-1 and NOR-90 in autoimmune sera. *Journal of Rheumatology*, **1998**, 25, 2126-30	4.1	5
43	ASE-1: a novel protein of the fibrillar centres of the nucleolus and nucleolus organizer region of mitotic chromosomes. *Chromosoma*, **1997**, 106, 493-502	2.8	37
42	Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting. *Arthritis and Rheumatism*, **1997**, 40, 413-8		49
41	Range of antinuclear antibodies in "healthy" individuals. *Arthritis and Rheumatism*, **1997**, 40, 1601-11		622
40	Molecular cloning of a novel 97-kd Golgi complex autoantigen associated with Sjögren's syndrome. *Arthritis and Rheumatism*, **1997**, 40, 1693-702		149
39	Autoantibodies: diagnostic fingerprints and etiologic perplexities. *Clinical and Investigative Medicine*, **1997**, 20, 50-66	0.9	8
38	High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. *Clinical and Investigative Medicine*, **1997**, 20, 308-19	0.9	19
37	Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. *Arthritis and Rheumatism*, **1996**, 39, 1151-60		140
36	The centromere kinesin-like protein, CENP-E. An autoantigen in systemic sclerosis. *Arthritis and Rheumatism*, **1996**, 39, 1355-61		35
35	The spindle kinesin-like protein HsEg5 is an autoantigen in systemic lupus erythematosus. *Arthritis and Rheumatism*, **1996**, 39, 1635-42		42
34	Clinical relevance of autoantibodies in systemic rheumatic diseases. *Molecular Biology Reports*, **1996**, 23, 133-45	2.8	30
33	Centriole and Centrosome Autoantibodies **1996**, 153-160		5
32	Molecular characterization of Golgin-245, a novel Golgi complex protein containing a granin signature. *Journal of Biological Chemistry*, **1995**, 270, 31262-8	5.4	93
31	The safety and efficacy of low-dose tissue plasminogen activator in the treatment of systemic sclerosis. *Journal of Dermatology*, **1995**, 22, 637-42	1.6	4
30	Detection of autoantibodies to SS-A/Ro by indirect immunofluorescence using a transfected and overexpressed human 60 kD Ro autoantigen in HEp-2 cells. *Journal of Clinical Laboratory Analysis*, **1995**, 9, 218-24	3	43
29	Autoantibodies to the nucleolar organizer antigen NOR-90 in children with systemic rheumatic diseases. *Journal of Rheumatology*, **1995**, 22, 521-4	4.1	7

28	Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis. *Journal of Rheumatology*, **1995**, 22, 1688-93	4.1	28
27	Immunocytochemical characterization of human NOR-90 (upstream binding factor) and associated antigens reactive with autoimmune sera. Two MR forms of NOR-90/hUBF autoantigens. *Molecular Biology Reports*, **1994**, 19, 115-24	2.8	27
26	Antibodies to HMG proteins in patients with drug-induced autoimmunity. *Arthritis and Rheumatism*, **1994**, 37, 98-103		36
25	Antibodies to high mobility group proteins in systemic sclerosis. *Journal of Rheumatology*, **1994**, 21, 2071-5	4.1	26
24	Molecular characterization of two human autoantigens: unique cDNAs encoding 95- and 160-kD proteins of a putative family in the Golgi complex. *Journal of Experimental Medicine*, **1993**, 178, 49-62	16.6	133
23	Identification of a subset of patients with scleroderma with severe pulmonary and vascular disease by the presence of autoantibodies to centromere and histone. *Annals of the Rheumatic Diseases*, **1993**, 52, 780-4	2.4	16
22	Autoantibodies in scleroderma. *Journal of Dermatology*, **1993**, 20, 257-68	1.6	27
21	Localized scleroderma progressing to systemic disease. Case report and review of the literature. *Arthritis and Rheumatism*, **1993**, 36, 410-5		51
20	CENP-F is a .ca 400 kDa kinetochore protein that exhibits a cell-cycle dependent localization. *Cytoskeleton*, **1993**, 26, 214-26		165
19	Diversity and origin of rheumatologic autoantibodies. *Clinical Microbiology Reviews*, **1991**, 4, 256-69	34	25
18	Prolonged improvement of Raynaud's phenomenon and scleroderma after recombinant tissue plasminogen activator therapy. *Arthritis and Rheumatism*, **1990**, 33, 274-6		21
17	Normal anti-Klebsiella lymphocytotoxicity in ankylosing spondylitis. *Arthritis and Rheumatism*, **1986**, 29, 358-62		5
16	T lymphocytes from hemophiliacs proliferate after exposure to factor VIII product. *Vox Sanguinis*, **1986**, 51, 92-5	3.1	17
15	Autoantibody testing: procedures and significance in systemic rheumatic diseases. *Methods and Achievements in Experimental Pathology*, **1986**, 12, 224-60		18
14	Antinuclear, anticytoplasmic, and anti-Sjogren's syndrome antigen A (SS-A/Ro) antibodies in female blood donors. *Clinical Immunology and Immunopathology*, **1985**, 36, 120-8		136
13	Speckled pattern antinuclear antibodies resembling anticentromere antibodies. *Arthritis and Rheumatism*, **1984**, 27, 92-6		46
12	Reduced skin threshold to irritation in the presence of allergic contact dermatitis in the guinea pig. *Contact Dermatitis*, **1984**, 11, 31-3	2.7	5
11	Antibodies from patients with autoimmune disease react with a cytoplasmic antigen in the Golgi apparatus. *Journal of Immunology*, **1984**, 132, 2904-8	5.3	45

10	Clinical features of patients with antibodies directed against proliferating cell nuclear antigen. *Arthritis and Rheumatism*, **1983**, 26, 140-5		55
9	Anticentromere antibodies in primary biliary cirrhosis. *Arthritis and Rheumatism*, **1983**, 26, 914-7		93
8	Autoantibody to centromere (kinetochore) in scleroderma sera. *Proceedings of the National Academy of Sciences of the United States of America*, **1980**, 77, 1627-31	11.5	620
7	Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. *Arthritis and Rheumatism*, **1980**, 23, 617-25		471
6	The CREST syndrome: a distinct serologic entity with anticentromere antibodies. *American Journal of Medicine*, **1980**, 69, 520-6	2.4	327
5	Autoantibody to a nuclear antigen in proliferating cells. *Journal of Immunology*, **1978**, 121, 2228-34	5.3	572
4	Antibodies to histones in drug-induced and idiopathic lupus erythematosus. *Journal of Clinical Investigation*, **1978**, 62, 560-7	15.9	223
3	Detection of Autoantibodies by Enzyme-Linked Immunosorbent Assay and Bead Assays859-867		1
2	An Immune Cell Atlas Reveals Dynamic COVID-19 Specific Neutrophil Programming Amenable to Dexamethasone Therapy		1
1	Anti-cardiolipin and other anti-phospholipid antibodies in critically ill COVID-19 positive and negative patients		1